Tricida, Inc.
IPO News: Filed S-1/A: Tricida Launches 10.3mm Share IPO with $16.00 - $18.00 Marketing Range


Initial Filing Date: 06/04/18

Launch Date: 06/18/18

Price Range: $16.00 - $18.00

Shares Offered (Pre-Shoe, mm): 10.3

Primary Shares (mm): 10.3

Secondary Shares (mm): 0.0

Amount Offered (@ Midpoint) (mm): $175.1

% Secondary: 0.0%

Shares Outstanding (mm): 10.3

Market Value (@ Midpoint) (mm): $175.1

Offering as % of Market Value: 100.0%

Bookrunners: Goldman Sachs | J.P. Morgan | Cowen

Major Holders: OrbiMed (David P. Bonita, M.D., Director) | Sibling Capital | Longitude Venture Partners II (David Hirsch, M.D., Ph.D., Director) | Wellington Management | S.R. One (Brian M. Gallagher, Jr., Ph.D, Director) | Omega Fund | MRL Ventures

Description: Late-stage pharmaceutical company focused on the development and commercialization of our drug candidate, TRC101, a non-absorbed polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal tract, or GI tract.

Note: Emerging Growth Company

Reference Links: S-1/A